Key clinical point: Energy-based therapy with adjunctive oxymetazoline was safe and improved facial erythema for patients with moderate to severe facial erythema associated with rosacea.

Major finding: Among 43 evaluable patients, clinician erythema assessment score was improved in 39 (90.7%) patients 6 hours post treatment and in 30 (68.2%) patients pretreatment.

Study details: An open-label, phase 4 study of 46 patients with moderate to severe facial erythema associated with rosacea.

Disclosures: The manuscript was funded by oxymetazoline manufacturer Aclaris Therapeutics. Several authors disclosed being an investigator, consultant, and/or laser manufacturers. One author was an employee of Aclaris at the time of the study.